Enveric Biosciences, Inc.

NasdaqCM:ENVB Stock Report

Market Cap: US$3.1m

Enveric Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ENVB?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders276,0242.78%
Institutions1,001,29710.1%
General Public8,667,59987.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 328.4%.

Top Shareholders

Top 25 shareholders own 12.84% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
3.69%
AdvisorShares Investments, LLC
367,047US$113.8k15.8%0.02%
2.92%
Intracoastal Capital LLC
290,000US$89.9k0%1.21%
2.19%
Geode Capital Management, LLC
217,893US$67.5k388%no data
0.49%
Frank Pasqualone
48,733US$15.1k4,770%no data
0.48%
Marcus Schabacker
48,053US$14.9k14,900%no data
0.48%
George Kegler
48,053US$14.9k14,900%no data
0.48%
Michael Webb
47,733US$14.8k0%no data
0.31%
Two Sigma Securities, LLC, Asset Management Arm
30,632US$9.5k101%no data
0.29%
Joseph Tucker
29,260US$9.1k0%no data
0.28%
Sheila DeWitt
27,845US$8.6k0%no data
0.23%
Virtu Financial LLC, Asset Management Arm
23,117US$7.2k67.6%no data
0.2%
Peter Facchini
19,722US$6.1k0%no data
0.18%
The Vanguard Group, Inc.
18,198US$5.6k0%no data
0.17%
Tower Research Capital Europe Limited
17,372US$5.4k51.7%no data
0.13%
Two Sigma Investments, LP
13,385US$4.1k0%no data
0.13%
Citadel Advisors LLC
12,753US$4.0k0%no data
0.091%
BlackRock, Inc.
9,010US$2.8k-69.5%no data
0.067%
Kevin Coveney
6,625US$2.1k0%no data
0.0073%
UBS Asset Management AG
731US$226.6-98.3%no data
0.0043%
Advisor Group Holdings, Inc., Asset Management Arm
425US$131.6-8.6%no data
0.0027%
Group One Trading LP, Asset Management Arm
273US$84.80%no data
0.0015%
Osaic Wealth, Inc. , Asset Management Arm
150US$46.60%no data
0.001%
Merrill Lynch & Co. Inc., Banking Investments
100US$31.10%no data
0.00073%
Bank of America Corporation, Asset Management Arm
73US$22.514.1%no data
0.00071%
National Bank Investments Inc.
71US$21.91.43%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 08:03
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enveric Biosciences, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
James MolloyAlliance Global Partners
Hunter DiamondDiamond Equity Research LLC